HDAC9 and neoplasm: The combination treatment of sublethal doses of HDACi with CTL were shown to enhance PDAC cells’ sensitivity to CTL-mediated killing, suggesting that HDAC may potentially increase tumour immunogenicity and reverse the immune evasion phenotype of PDAC cells.